On December 1, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) reported the establishment of an agreement with the European Organisation for Research and Treatment of Cancer (EORTC) for the phase 3 registrational trial of ICT-107 in patients with newly diagnosed glioblastoma (GBM) (Press release, ImmunoCellular Therapeutics, DEC 1, 2015, View Source [SID:1234508367]). Schedule your 30 min Free 1stOncology Demo! The EORTC contributed to the trial design and will assist ImmunoCellular Therapeutics in facilitating accrual of patients for this trial in Europe.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Prof. Michael Weller of the University Hospital Zurich, Chair of the EORTC Brain Tumor Group, and coordinator of this study commented "The EORTC is a leader in enabling multi-disciplinary approaches to investigate strategic therapeutic questions through clinical and translational research. We aim to improve the understanding of disease and help advance innovative therapies in cancer care for the benefit of patients. We are pleased to collaborate with ImmunoCellular to conduct the phase 3 registrational trial of ICT-107, a potentially promising cancer immunotherapeutic approach to treating brain cancer."
"Working with the EORTC is a key step in our strategy to establish a network of relationships within the clinical oncology community to support the conduct of the ICT-107 Phase 3 trial," said Andrew Gengos, ImmunoCellular’s Chief Executive Officer. "For several months, we have been working with prominent cancer cooperative groups in the US and Europe to refine and finalize the trial design, gain their endorsement and secure their help in executing a high quality trial. With EORTC’s support, we believe that we can access large numbers of affiliated trial sites which will facilitate patient accrual. We anticipate patient enrollment in the phase 3 trial to begin within the next few weeks."